Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ImmuNext
Lebanon, New Hampshire, United Statesimmunext.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
ImmuNext is developing immunomodulatory therapeutics with multiple programs in various stages. Their lead product Frexalimab (CD40L inhibitor) is in Phase 3 for Multiple Sclerosis, while Onvatilimab (VISTA antagonist) is pending for solid tumors. The company has established significant partnerships with major pharmaceutical companies for their pipeline assets.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Monoclonal antibodiesImmunomodulatory therapeutics
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on ImmuNext.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmuNext.